These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pros and cons of off-label promotion investigations and prosecutions. Loucks MK Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041 [No Abstract] [Full Text] [Related]
3. PLIVA v. Mensing: generic consumers' unfortunate hand. Lee SB Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916 [No Abstract] [Full Text] [Related]
4. Sandoz sues FDA over delay in first biogeneric approval. Fox JL Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046 [No Abstract] [Full Text] [Related]
5. The right to a trial: Should dying patients have access to experimental drugs? Groopman J New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539 [No Abstract] [Full Text] [Related]
6. Pharma allowed to make own genetics. Owens J Nat Rev Drug Discov; 2005 Jul; 4(7):530. PubMed ID: 16075483 [No Abstract] [Full Text] [Related]
7. Raising the bar for market authorisation of new drugs. Naci H; Cylus J; Vandoros S; Sato A; Perampaladas K BMJ; 2012 Aug; 345():e4261. PubMed ID: 22872693 [No Abstract] [Full Text] [Related]
8. FDA attempting to overcome major roadblocks in monitoring drug safety. Zielinski SL J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645 [No Abstract] [Full Text] [Related]
10. A strike against preemption. Nat Biotechnol; 2009 May; 27(5):397. PubMed ID: 19430422 [TBL] [Abstract][Full Text] [Related]
11. Drug regulation 2056. Bezold C; Peck J Food Drug Law J; 2005; 60(2):127-36. PubMed ID: 16097091 [No Abstract] [Full Text] [Related]
12. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration? Zelenay JL Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773 [No Abstract] [Full Text] [Related]
13. Recent developments help the defense of drug companies in 10b-5 cases. Salpeter AN; Hutchins H Food Drug Law J; 1996; 51(3):345-53. PubMed ID: 11797711 [No Abstract] [Full Text] [Related]
14. The FDA and "privatization"--the drug approval process. Rutherford EM Food Drug Law J; 1995; 50 Spec():203-25. PubMed ID: 10343044 [No Abstract] [Full Text] [Related]
16. Remarks at the Food and Drug Law Institute's 48th Annual Conference. Niedelman SM Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089 [No Abstract] [Full Text] [Related]
17. Navigating the Hatch-Waxman Act's safe harbor. Jones PB Food Drug Law J; 2002; 57(3):475-89. PubMed ID: 12710407 [No Abstract] [Full Text] [Related]
18. The learned intermediary doctrine: past, present and future. Alsobrook HB Leg Med; 1994; ():269-80. PubMed ID: 7830482 [No Abstract] [Full Text] [Related]
19. Regulatory evaluation of biotechnology drugs: current trends in the United States. Sobel S Bioprocess Technol; 1991; 13():499-511. PubMed ID: 1367148 [No Abstract] [Full Text] [Related]
20. Regulatory watch: impact of PDUFA on regulatory decision-making. Hay M Nat Rev Drug Discov; 2010 Aug; 9(8):585. PubMed ID: 20671755 [No Abstract] [Full Text] [Related] [Next] [New Search]